• Welcome to Phoenix Rising!

    Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of, and finding treatments for, complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia, long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.

    To become a member, simply click the Register button at the top right.

Part 2: Brain Cells Making us Sick? Messed up microglia could be driving symptoms

Simon submitted a new blog post:

Part 2: Brain Cells Making us Sick? Messed up microglia could be driving symptoms

Simon McGrath looks at theories that microglia, the brain's immune cells, might be overactive and driving the symptoms of ME/CFS and fibromyalgia.

In Part 1, he described how the body reacts to infection or wounding with a “sickness response” that partly resembles ME/CFS, and how the microglia are the last step in the physiological mechanisms that lead to sickness response.
Could microglia be behind the symptoms of ME/CFS? Artist's image of a microglia. © 2012 Hagop Kaneboughazian

Sickness response is a good thing, helping us survive by resting to fight off infection. But it evolved as a short-term response, and may be harmful if it sets in for the long-term, perhaps playing a role in ME/CFS.

Overactive microglia?

So how could sickness response get stuck in the on position? One possibility is that a chronic infection continues to trigger it, but a chronic infection should exclude an ME/CFS diagnosis.

The last step in the chain, the microglia, are the focus of two other theories which see microglia activated when they should be in their normal, patrolling state.

ME/CFS and fibromyalgia are often referred to as a neuroimmune disease because of the frequent finding of immune dysfunction and widespread symptoms implicating the brain.

Microglia are cells that potentially connect the immune system to the nervous system, responding to immune activation to effectively "turn on" sickness response in the brain. The idea that inappropriate microglial activation could play a major role in ME/CFS is fascinating.

The activation could be due to earlier priming, a severe initial infection, a disturbance in the immune system resulting from problems in the microbiome, autoimmunity or even chronic infection. Microglial activation could be the common endpoint of many different routes to ME/CFS and fibromyalgia.

Microglial research is poised to become a new front in understanding ME/CFS and fibromyalgia, particularly as high-tech tools are developed to probe the state of microglia in the brain.

Dubbo studies: severity of acute illness is key

The Dubbo group in Australia has done research suggesting that in sudden-onset CFS, the severity of the initial infection triggers long-term activation of microglia. They studied patients with infectious mononucleosis or related infections and found that the stronger the initial sickness response, the greater the chances that a patient would go on to develop CFS.
The CFS did not seem to be caused by continuing high cytokine levels. While cytokine levels were initially elevated, they dropped back to normal levels. But, the researchers suggested, the severity of the initial cytokine response might have got the microglia "stuck" in an activated mode, locking the brain into an extended sickness response.

Interferon-gamma, a proinflammatory cytokine that can activate microglia, seemed to play a particularly important role. Patients with two copies of the most active interferon-gamma gene version were likely to be sicker initially and about three times more likely to develop CFS at six months.

This hypothesis got some support from a recent small study which found that microglia in the brains of ME/CFS patients were activated -- exactly what the Dubbo hypothesis predicts.

Microglial 'Priming' theory
Professor Hugh Perry
A second way that microglia could cause a continuing sickness response is by becoming over-reactive. Hugh Perry, Professor of experimental neuropathology from the University of Southampton, and Dr. Jarred Younger of Stanford University have independently proposed that the problem starts with "priming" of microglia by a variety of factors, including previous infections, obesity, chronic stress, and age.

Primed microglia are hypersensitive -- a bit like a primed or armed bomb -- so they react too easily and/or too aggressively, which could lead to long-term sickness response. So an infection or other trigger that would lead to no long-term problems in someone with "normal" microglia could lead to ME/CFS or fibromyalgia in someone with primed microglia.

Primed microglia are measurably different from patrolling ones, with very different receptors on their cell surface. Fewer of the receptors that respond to "keep calm" signals from healthy neurons and more receptors that respond to any "shoot now" signals. The result is an excitable, trigger-happy microglial cell.

Much of the work on priming has been done on animals, since the only sure way to detect priming is to physically examine them. However, studies looking at brains of people who have died of neurodegenerative disease also reveal primed microglia.

Perry believes that priming is an important factor in these illnesses because it could lead to an overly-aggressive immune response, damaging tissue instead of helping it heal.

At the recent International Symposium for CFS/ME in Australia Perry suggested that priming of microglia could be behind this illness as well (though he doesn’t think neurones degenerate in ME/CFS the way they do in the other illnesses he studies). Once primed, Perry argues, an infection could send the microglia into a permanently activated state, triggering a long-term sickness response.

Dr. Jarred Younger
Younger, a pain researcher at Stanford, independently developed a very similar theory, which he described at the Stanford Symposium and IACFS/ME conference in March. He primarily focused on fibromyalgia in the IACFS/ME talk, but believes the same mechanism could be behind ME/CFS. Priming could lead to the ME/CFS and fibromyalgia in two possible ways, says Younger:
  • Similar to Perry’s view, microglia might get "stuck" in the activated state: "they fail to revert to their former patrolling state and are therefore constantly producing chemicals that cause ME/CFS symptoms. Microglia are long-lived cells (many, many years), so microglia stuck in [an] state can cause problems for a long period of time."
  • Or, primed microglia may react when they shouldn't, producing the flares characteristic of ME/CFS and FM as they become fully activated and pump out the chemicals that cause sickness.
What I find fascinating is that Perry and Younger independently came up with very similar ideas of microglial priming. They came at it from different directions: Perry is the microglia expert in neurodegenerative diseases, Younger is the fibromyalgia expert looking at how core biological processes might explain the illness. When ideas converge like this, it's often a good sign.

Microglial-hypothesis.png
The Microglia Priming hypothesis for fibromyalgia and ME/CFS, © Dr. Jarred Younger. Reproduced with permission.
As yet, there is no hard evidence of microglial activation in fibromyalgia, but that might be about to change: Younger recently reported that a microglial-activation PET study -- similar to the recent one on ME/CFS -- is currently under way at Harvard.
However, activation is not the same as priming, and there is currently no way to detect "primed" microglia in living humans. Until there is, there won't really be a way to put this theory to the test. If larger studies show there is consistent activation of microglia, there may well be more attention on the priming hypothesis.

Intriguing treatment possibilities

If microglial activation is a factor in ME/CFS, then it could be treatable -- one reason there is so much interest in this line of research.

Perry and Younger pointed to the potential of microglial inhibitor drugs to calm down the overactive cells or prevent activation in the first place. No microglial inhibitors have been proven to treat ME/CFS or fibromyalgia, but Younger has already run an intriguing small study of low-dose naltrexone (LDN) for fibromyalgia with encouraging results.

The exact mechanism for LDN is uncertain, but Younger has pointed to evidence that at the low doses used naltrexone's main role is probably to inhibit activation of microglia. Other drugs have been shown to inhibit microglial activation in animals, but not yet in humans.

This is definitely an area to watch.

Thanks to @searcher who reported on Dr Younger’s work from Stanford and IACFS/ME, and helped me get the science right in this piece.

Simon McGrath tweets on ME/CFS research:



Phoenix Rising is a registered 501 c.(3) non profit. We support ME/CFS and NEID patients through rigorous reporting, reliable information, effective advocacy and the provision of online services which empower patients and help them to cope with their isolation.

There are many ways you can help Phoenix Rising to continue its work. If you feel able to offer your time and talent, we could really use some more authors, proof-readers, fundraisers, technicians etc. We’d also love to expand our Board of Directors. So, if you think you can help in any way then please contact Mark through the Forums.

And don’t forget: you can always support our efforts at no cost to yourself as you shop online! To find out more, visit Phoenix Rising’s Donate page by clicking the button below.

Continue reading the Original Blog Post
 
Last edited:
Thanks Simon.

Low dose naltrexone is something I've heard people mention for CFS for ages, so I was a bit surprised that my googling didn't bring up any research. I'd have thought that we'd have to be dealing with subsets again as if LDN was significantly helpful for the majority of people surely there'd be more positive word on the grapevine.
 
Overall, very interesting concepts re: role of microglia dysfunction in CFS / ME. Similar theory raised in role of vagus nerve in CFS / ME. However, there is "missing piece of puzzle" for those of us that have severe localized muscle weakness and pain. It is true that generalized muscle pain and weakness characterize "sickness behavior" but I have never experienced severe localized muscle symptoms (ie hip girdle area) with previous exposure to illnesses such as influenza. Nor does it explain the muscle fasciculations I have experienced for last 2 years since my initial acute illness.

I have always described to my friends that after my acute illness, it seemed I aged overnight. I went from feeling like someone in their late 30's to a debilitated 90 year old. Some recent news about anti-aging and parabiosis sparked a question re: link between microglia cells and skeletal muscle function.

Does anyone have any information about which cell lines produce GDF11? A study examining whether CFS / ME patients have lower GDF11 levels vs healthy controls would be interesting.
 
Simon submitted a new blog post:

Part 2: Brain Cells Making us Sick? Messed up microglia could be driving symptoms

Simon McGrath looks at theories that microglia, the brain's immune cells, might be overactive and driving the symptoms of ME/CFS and fibromyalgia.

In Part 1, he described how the body reacts to infection or wounding with a “sickness response” that partly resembles ME/CFS, and how the microglia are the last step in the physiological mechanisms that lead to sickness response.
Could microglia be behind the symptoms of ME/CFS? Artist's image of a microglia. © 2012 Hagop Kaneboughazian

Sickness response is a good thing, helping us survive by resting to fight off infection. But it evolved as a short-term response, and may be harmful if it sets in for the long-term, perhaps playing a role in ME/CFS.

Overactive microglia?

So how could sickness response get stuck in the on position? One possibility is that a chronic infection continues to trigger it, but a chronic infection should exclude an ME/CFS diagnosis.

The last step in the chain, the microglia, are the focus of two other theories which see microglia activated when they should be in their normal, patrolling state.

ME/CFS and fibromyalgia are often referred to as a neuroimmune disease because of the frequent finding of immune dysfunction and widespread symptoms implicating the brain.

Microglia are cells that potentially connect the immune system to the nervous system, responding to immune activation to effectively "turn on" sickness response in the brain. The idea that inappropriate microglial activation could play a major role in ME/CFS is fascinating.

The activation could be due to earlier priming, a severe initial infection, a disturbance in the immune system resulting from problems in the microbiome, autoimmunity or even chronic infection. Microglial activation could be the common endpoint of many different routes to ME/CFS and fibromyalgia.

Microglial research is poised to become a new front in understanding ME/CFS and fibromyalgia, particularly as high-tech tools are developed to probe the state of microglia in the brain.

Dubbo studies: severity of acute illness is key

The Dubbo group in Australia has done research suggesting that in sudden-onset CFS, the severity of the initial infection triggers long-term activation of microglia. They studied patients with infectious mononucleosis or related infections and found that the stronger the initial sickness response, the greater the chances that a patient would go on to develop CFS.
The CFS did not seem to be caused by continuing high cytokine levels. While cytokine levels were initially elevated, they dropped back to normal levels. But, the researchers suggested, the severity of the initial cytokine response might have got the microglia "stuck" in an activated mode, locking the brain into an extended sickness response.

Interferon-gamma, a proinflammatory cytokine that can activate microglia, seemed to play a particularly important role. Patients with two copies of the most active interferon-gamma gene version were likely to be sicker initially and about three times more likely to develop CFS at six months.

This hypothesis got some support from a recent small study which found that microglia in the brains of ME/CFS patients were activated -- exactly what the Dubbo hypothesis predicts.

Microglial 'Priming' theory
Professor Hugh Perry
A second way that microglia could cause a continuing sickness response is by becoming over-reactive. Hugh Perry, Professor of experimental neuropathology from the University of Southampton, and Dr. Jarred Younger of Stanford University have independently proposed that the problem starts with "priming" of microglia by a variety of factors, including previous infections, obesity, chronic stress, and age.

Primed microglia are hypersensitive -- a bit like a primed or armed bomb -- so they react too easily and/or too aggressively, which could lead to long-term sickness response. So an infection or other trigger that would lead to no long-term problems in someone with "normal" microglia could lead to ME/CFS or fibromyalgia in someone with primed microglia.

Primed microglia are measurably different from patrolling ones, with very different receptors on their cell surface. Fewer of the receptors that respond to "keep calm" signals from healthy neurons and more receptors that respond to any "shoot now" signals. The result is an excitable, trigger-happy microglial cell.

Much of the work on priming has been done on animals, since the only sure way to detect priming is to physically examine them. However, studies looking at brains of people who have died of neurodegenerative disease also reveal primed microglia.

Perry believes that priming is an important factor in these illnesses because it could lead to an overly-aggressive immune response, damaging tissue instead of helping it heal.

At the recent International Symposium for CFS/ME in Australia Perry suggested that priming of microglia could be behind this illness as well (though he doesn’t think neurones degenerate in ME/CFS the way they do in the other illnesses he studies). Once primed, Perry argues, an infection could send the microglia into a permanently activated state, triggering a long-term sickness response.

Dr. Jarred Younger
Younger, a pain researcher at Stanford, independently developed a very similar theory, which he described at the Stanford Symposium and IACFS/ME conference in March. He primarily focused on fibromyalgia in the IACFS/ME talk, but believes the same mechanism could be behind ME/CFS. Priming could lead to the ME/CFS and fibromyalgia in two possible ways, says Younger:
  • Similar to Perry’s view, microglia might get "stuck" in the activated state: "they fail to revert to their former patrolling state and are therefore constantly producing chemicals that cause ME/CFS symptoms. Microglia are long-lived cells (many, many years), so microglia stuck in [an] state can cause problems for a long period of time."
  • Or, primed microglia may react when they shouldn't, producing the flares characteristic of ME/CFS and FM as they become fully activated and pump out the chemicals that cause sickness.
What I find fascinating is that Perry and Younger independently came up with very similar ideas of microglial priming. They came at it from different directions: Perry is the microglia expert in neurodegenerative diseases, Younger is the fibromyalgia expert looking at how core biological processes might explain the illness. When ideas converge like this, it's often a good sign.

Microglial-hypothesis.png
The Microglia Priming hypothesis for fibromyalgia and ME/CFS, © Dr. Jarred Younger. Reproduced with permission.
As yet, there is no hard evidence of microglial activation in fibromyalgia, but that might be about to change: Younger recently reported that a microglial-activation PET study -- similar to the recent one on ME/CFS -- is currently under way at Harvard.
However, activation is not the same as priming, and there is currently no way to detect "primed" microglia in living humans. Until there is, there won't really be a way to put this theory to the test. If larger studies show there is consistent activation of microglia, there may well be more attention on the priming hypothesis.

Intriguing treatment possibilities

If microglial activation is a factor in ME/CFS, then it could be treatable -- one reason there is so much interest in this line of research.

Perry and Younger pointed to the potential of microglial inhibitor drugs to calm down the overactive cells or prevent activation in the first place. No microglial inhibitors have been proven to treat ME/CFS or fibromyalgia, but Younger has already run an intriguing small study of low-dose naltrexone (LDN) for fibromyalgia with encouraging results.

The exact mechanism for LDN is uncertain, but Younger has pointed to evidence that at the low doses used naltrexone's main role is probably to inhibit activation of microglia. Other drugs have been shown to inhibit microglial activation in animals, but not yet in humans.

This is definitely an area to watch.


Simon McGrath tweets on ME/CFS research:



Phoenix Rising is a registered 501 c.(3) non profit. We support ME/CFS and NEID patients through rigorous reporting, reliable information, effective advocacy and the provision of online services which empower patients and help them to cope with their isolation.

There are many ways you can help Phoenix Rising to continue its work. If you feel able to offer your time and talent, we could really use some more authors, proof-readers, fundraisers, technicians etc. We’d also love to expand our Board of Directors. So, if you think you can help in any way then please contact Mark through the Forums.

And don’t forget: you can always support our efforts at no cost to yourself as you shop online! To find out more, visit Phoenix Rising’s Donate page by clicking the button below.

Continue reading the Original Blog Post
Hi Simon,

I find the idea of microglial priming and activation may be the final pathway to cfs/me fascinating. In 2006-7 Dr. Jose Montoya treated a group of patients with Valcye who were diagnosed with cfs/me with some success. He believed that HHV6 or other herpes viruses were causing the disease through chronic ongoing infection. Recently a paper was published by Zhaoging Ding PhD, department of neurology at Stanford entitled " Antiviral drug ganciclovir is a potent inhibitor of microglial proliferation and neuro inflammation." This recent paper would would dovetail very well with the recent theory of microglial priming and activation. This would explain why valcyte has had some success in treating cfs/me even though no infection has been proven. This would also go along with Dr. Lipkin inability to find an infectious agent as a cause for cfs/me. It was also found that acyclovir didn't supress microglial cells. Possibly Valcyte may end up being one of the drugs to treat microglial cell over activation as it primary targets not as a antiviral drug.

Regards,
Gary
Similar studies have been conducted using animal models for quite sometime now. These studies particularly focused on stress induced changes on microglial and consequential release of pro-inflammatory cytokines, mainly IL-1beta.

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3788324/

It was found in animal models that this response could be blunted by administering Minocycline (anti-inflammatory, commonly used to treat acne). I searched these forums and found a thread form 2010 talking about mixed results using minocycline.

http://forums.phoenixrising.me/index.php?threads/minocyclin.7983/
 
Similar studies have been conducted using animal models for quite sometime now. These studies particularly focused on stress induced changes on microglial and consequential release of pro-inflammatory cytokines, mainly IL-1beta.

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3788324/

It was found in animal models that this response could be blunted by administering Minocycline (anti-inflammatory, commonly used to treat acne). I searched these forums and found a thread form 2010 talking about mixed results using minocycline.

http://forums.phoenixrising.me/index.php?threads/minocyclin.7983/

Here is an article talking about the debate over the accuracy animal research and Microglia. They suggest that there are quite a few differences in the way mice microglia bind to different things.

http://phenomena.nationalgeographic.com/2014/04/07/microglia-in-mice-and-men/
 
Similar studies have been conducted using animal models for quite sometime now. These studies particularly focused on stress induced changes on microglial and consequential release of pro-inflammatory cytokines, mainly IL-1beta.

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3788324/
Thanks, that's very interesting.

For those that want more, this is the study: Acute and Chronic Stress-Induced Disturbances of Microglial Plasticity, Phenotype and Function
The aim of the current review is to critically examine the now substantial literature that has developed around the ability of acute, sub-chronic and chronic stressors to alter microglial structure and function. The vast majority of studies have demonstrated that stress promotes significant structural remodelling of microglia, and can enhance the release of pro-inflammatory cytokines from microglia. Mechanistically, many of these effects appear to be driven by traditional stress-linked signalling molecules, namely corticosterone and norepinephrine. The specific effects of these signalling molecules are, however, complex as they can exert both inhibitory and suppressive effects on microglia depending upon the duration and intensity of exposure.

It was found in animal models that this response could be blunted by administering Minocycline (anti-inflammatory, commonly used to treat acne). I searched these forums and found a thread form 2010 talking about mixed results using minocycline.

http://forums.phoenixrising.me/index.php?threads/minocyclin.7983/
As @searcher pointed out, the problem is that microglial inhibitors aren't well understood, and usually have other functions too, so it's hard to read too much into results from one inhibitor. I think @Esther12 mentioned similar mixed results with LDN
I think one problem with definitively determining based on medication response if activated microglia are to blame for specific symptoms is that there aren't currently any medications that solely target microglia. For example, LDN works on opioid receptors in addition to microglia (although the researchers do think it's helping due to its effects on microglia.) Minocycline is an antibiotic and a microglial inhibitor. Ganciclovir is an antiviral that also inhibits microglia. I have had good luck with Reishi, but it has myriad effects throughout the body. I guess one option is that we can triangulate if a wide range of drugs/supplements that reduce microglial activity are also proven to reduce ME/CFS symptoms.

There's a discussion of this issue at http://www.researchgate.net/post/Microglia_and_minocycline that Dr Younger happened to weigh in on.

edit: Here's that comment from Dr Younger:

Jarred Younger · Stanford University

I do not know of any available agent that selectively suppresses microglia function. There are multiple agents that suppress microglia activity *in addition* to other known effects. Some of those are naltrexone/naloxone, dextromethorphan, 3-hydroxymorphinan, ibudilast, flurocitrate, and pentoxifyline. It is possible that dextro-naltrexone and dextro-naloxone may be more specific to microglia function -- check recent work by Linda Watkins, Mark Hutchinson, and their colleagues. I imagine there is more than one pharma group that is currently working on selective microglia inhibitors, so we may see new agents in the next few years.
 
First, here's a very readable homage to microglia, the subject of this blog
Best Cells Ever – (microglia)
http://phenomena.nationalgeographic.com/2013/01/11/best-cells-ever/
PS Where is part one of this?
Brain Cells Making us Sick? The microglia connection in ME/CFS & Fibromyalgia

Here is an article talking about the debate over the accuracy animal research and Microglia. They suggest that there are quite a few differences in the way mice microglia bind to different things.

http://phenomena.nationalgeographic.com/2014/04/07/microglia-in-mice-and-men/

Thanks, really interesting stuff: Microglia in Mice and Men
As they point out in the March issue of Trends in Neuroscience, mice and people are separated by 65 million years of evolution, leading to many genetic differences. What’s more, because of pressure from evolving pathogens, “the immune system is a ‘hot-spot’ for evolutionary changes,” the researchers write.
....
The mouse-versus-human question goes way, way beyond microglia. More than 80 percent of drugs that seem promising in mouse models end up failing in clinical trials, as Steve Perrin pointed out in a Nature commentary last month. Perrin’s organization, the ALS Therapy Development Institute, has tested more than 100 compounds in a mouse model of ALS (a motor neuron disease). None of them worked, even those that other research groups had shown to slow disease.
This is an important debate, but it may also be that animal model 'therapies' don't work in humans beccause the original animal work is duff, which is exactly what's argued here (and elsewhere):

Preclinical research: Make mouse studies work : Nature News & Comment
The published data look great - but didn't replicate in animal model testing either:

Mice2.jpg
 
FASEB J. 2012 Aug;26(8):3103-17. doi: 10.1096/fj.11-197194. Epub 2012 Apr 19.
Microglia and mast cells: two tracks on the road to neuroinflammation.
Skaper SD1, Giusti P, Facci L.
Author information
Abstract
One of the more important recent advances in neuroscience research is the understanding that there is extensive communication between the immune system and the central nervous system (CNS). Proinflammatory cytokines play a key role in this communication. The emerging realization is that glia and microglia, in particular, (which are the brain's resident macrophages), constitute an important source of inflammatory mediators and may have fundamental roles in CNS disorders from neuropathic pain and epilepsy to neurodegenerative diseases. Microglia respond also to proinflammatory signals released from other non-neuronal cells, principally those of immune origin. Mast cells are of particular relevance in this context. These immunity-related cells, while resident in the CNS, are capable of migrating across the blood-spinal cord and blood-brain barriers in situations where the barrier is compromised as a result of CNS pathology. Emerging evidence suggests the possibility of mast cell-glia communications and opens exciting new perspectives for designing therapies to target neuroinflammation by differentially modulating the activation of non-neuronal cells normally controlling neuronal sensitization, both peripherally and centrally. This review aims to provide an overview of recent progress relating to the pathobiology of neuroinflammation, the role of microglia, neuroimmune interactions involving mast cells, in particular, and the possibility that mast cell-microglia crosstalk may contribute to the exacerbation of acute symptoms of chronic neurodegenerative disease and accelerate disease progression, as well as promote pain transmission pathways. We conclude by considering the therapeutic potential of treating systemic inflammation or blockade of signaling pathways from the periphery to the brain in such settings.

http://www.ncbi.nlm.nih.gov/pubmed/22516295


The Mast Cell: A
Cell for All Seasons

Theoharis C. Theoharides, MS, PhD, MD, FAAAAI

http://www.mastcellmaster.com/documents/2014-04/TCT-Research-Overview-3-12-14.pdf


Immunology. 2014 Mar;141(3):314-27. doi: 10.1111/imm.12170.
Mast cells, glia and neuroinflammation: partners in crime?
Skaper SD1, Facci L, Giusti P.
Author information
Abstract

Glia and microglia in particular elaborate pro-inflammatory molecules that play key roles in central nervous system (CNS) disorders from neuropathic pain and epilepsy to neurodegenerative diseases. Microglia respond also to pro-inflammatory signals released from other non-neuronal cells, mainly those of immune origin such as mast cells. The latter are found in most tissues, are CNS resident, and traverse the blood-spinal cord and blood-brain barriers when barrier compromise results from CNS pathology. Growing evidence of mast cell-glia communication opens new perspectives for the development of therapies targeting neuroinflammation by differentially modulating activation of non-neuronal cells that normally control neuronal sensitization - both peripherally and centrally. Mast cells and glia possess endogenous homeostatic mechanisms/molecules that can be up-regulated as a result of tissue damage or stimulation of inflammatory responses. Such molecules include the N-acylethanolamine family. One such member, N-palmitoylethanolamine is proposed to have a key role in maintenance of cellular homeostasis in the face of external stressors provoking, for example, inflammation. N-Palmitoylethanolamine has proven efficacious in mast-cell-mediated experimental models of acute and neurogenic inflammation. This review will provide an overview of recent progress relating to the pathobiology of neuroinflammation, the role of microglia, neuroimmune interactions involving mast cells and the possibility that mast cell-microglia cross-talk contributes to the exacerbation of acute symptoms of chronic neurodegenerative disease and accelerates disease progression, as well as promoting pain transmission pathways. We will conclude by considering the therapeutic potential of treating systemic inflammation or blockade of signalling pathways from the periphery to the brain in such settings.

http://www.ncbi.nlm.nih.gov/pubmed/24032675




Mast cells in the brain: evidence and functional significance
http://www.sciencedirect.com/science/article/pii/0166223696818637


Mast cells on the mind: new insights and opportunities
http://www.sciencedirect.com/science/article/pii/S0166223613001124


Mast cells, microglia and brain inflammation

http://www.autismfile.com/science-research/mast-cells-microglia-and-brain-inflammation
 
Last edited:
Leptin, a neuroendocrine mediator of immune responses, inflammation, and sickness behaviors
http://www.sciencedirect.com/science/article/pii/S0018506X12001286

Leptin deficiency-induced obesity affects the density of mast cells in abdominal fat depots and lymph nodes in mice


http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3287967/


Human mast cells express leptin and leptin receptors.
http://www.ncbi.nlm.nih.gov/pubmed/19241089


Allergy. 2013 Jan;68(1):8-15. doi: 10.1111/all.12043. Epub 2012 Oct 16.
Do mast cells link obesity and asthma?

http://www.ncbi.nlm.nih.gov/pubmed/23066905


Leptin and Mast Cells: A Novel Adipoimmune Link
http://journals.tubitak.gov.tr/medical/issues/sag-01-31-6/sag-31-6-22-0102-7.pdf
 
A new paper has just been published taking from a rat model that provides support for microglial activation leading to fatigue, as proposed in several of the theories explored in this blog.

In a nutshell, it shows that poly-I:C - which activates the immune system (acts like a super-charged RNA virus), activates microglia long-term, and leads to them producing the cytokine Interleukin-!b. Importantly, their study indicates that Interleukin-1b then acts on astrocytes to trigger fatigue due to over-expression of serotonin transporters.
Induction of interleukin-1β by activated microglia is a prerequisite for immunologically induced fatigue - Ifuku - 2014
We previously reported* that an intraperitoneal (i.p.) injection of synthetic double-stranded RNA, polyriboinosinic polyribocytidylic acid (poly-I:C), produced prolonged fatigue in rats, which might serve as a model for chronic fatigue syndrome.
[poly-I:C provokes an immune response by mimicking dsRNA viruses.]

...
We therefore propose that poly-I:C-induced microglial activation, which may be at least partly caused by a direct action of poly-I:C, enhances IL-1β expression. Then, IL-1β induces 5-HTT expression in astrocytes, resulting in the immunologically induced fatigue.
Astrocytes are not neurones, but another type of brain cell that has many important functions, including some immune roles.
 
I have long been interested in lipopolysaccharide activation of immune responses in ME. I wanted to write a blog on it but my serious blogs are on hold till I improve. LPS has been found elevated in ME patients, though I do not know how reliable the finding is. LPS is a superantigen. It can massively change immune responses. That is because, I think, the immune system reacts to LPS in the blood as though there were a massive bacterial infection. So LPS getting through the gut wall and then the liver detox could easily induce big immune changes on an ongoing basis, and its even possible this is more common after eating ... right when leptin levels might change. This is just speculation, but I keep thinking about it.

The microglial theory is looking more and more interesting over time.